Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

0.9730
-0.0470-4.61%
Volume:2.07M
Turnover:2.03M
Market Cap:175.23M
PE:-2.41
High:1.01
Open:1.01
Low:0.9675
Close:1.02
52wk High:6.88
52wk Low:0.8294
Shares:180.09M
Float Shares:132.00M
Volume Ratio:0.39
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4039
EPS(LYR):-0.4216
ROE:-56.66%
ROA:-33.03%
PB:1.06
PE(LYR):-2.31

Loading ...

Newegg, Medpace, Compass, Spyre, MINISO Insider Shake-Up

TIPRANKS
·
Oct 03

Top Executive Quietly Boosts Stake in Emerging Biotech Player

TIPRANKS
·
Oct 03

Compass Therapeutics Chief Accounting Officer Neil Lerner Buys $0.92 20,000 Shares for $18,400

Reuters
·
Oct 02

Compass Therapeutics Chief Accounting Officer Neil Lerner Acquires 2,500 Common Shares Worth $2,850

Reuters
·
Sep 25

Compass Therapeutics Shares Drop After Downgrade From Wedbush

MT Newswires Live
·
Sep 24

Compass Therapeutics price target lowered to $8 from $15 at Craig-Hallum

TIPRANKS
·
Sep 23

Canaccord Genuity Reaffirms Their Buy Rating on Compass Therapeutics (CMPX)

TIPRANKS
·
Sep 23

Compass Therapeutics Price Target Cut to $12.00/Share from $24.00 by HC Wainwright & Co.

Dow Jones
·
Sep 23

Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5

MT Newswires Live
·
Sep 23

Compass Therapeutics price target lowered to $4 from $10 at Citizens

TIPRANKS
·
Sep 23

US Research Roundup- Allstate, Autozone, Vertex Pharmaceuticals

Reuters
·
Sep 23

Compass Therapeutics Inc. : Guggenheim Cuts Target Price to $4 from $8

THOMSON REUTERS
·
Sep 23

Compass Therapeutics Inc. : Wedbush Cuts to Neutral from Outperform; Cuts Target Price to $1 from $5

THOMSON REUTERS
·
Sep 23

Compass Therapeutics downgraded to Neutral from Outperform at Wedbush

TIPRANKS
·
Sep 23

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 23

Compass Therapeutics (CMPX) was downgraded to a Hold Rating at LifeSci Capital

TIPRANKS
·
Sep 23

U.S. Stocks on the MOVE-Greenland Mines, GameStop, Shopify

Reuters
·
Sep 22

Compass Therapeutics Faces FDA Pushback on Tovecimig Trial

TIPRANKS
·
Sep 22

Compass Falls After FDA Recommends Fresh Trial Before Marketing Application Submission

Reuters
·
Sep 22

Compass Therapeutics Says FDA Urges Survival-Benefit Trial Before Tovecimig BLA in Biliary Tract Cancer

Reuters
·
Sep 22